GlassScriptPhysician profile
James Mcdonald
NPI 1427590207
$5,832.26
in general payments reported to CMS, 2019-2025
24 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,177 · 2022: $1,138 · 2023: $817 · 2024: $1,557 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,516.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,790.40 | 2021-2025 | Proclaim, Eterna |
| Collegium Pharmaceutical, INC. | $461.13 | 2021-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $416.31 | 2021-2025 | Relistor |
| Boston Scientific Corporation | $346.42 | 2023-2025 | Infinion 16, General - Therapies, Artisan |
| Arbor Pharmaceuticals, INC. | $143.02 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $92.58 | 2021-2024 | Ztlido |
| Amgen INC. | $66.32 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $56.32 | 2023-2024 | Horizant, Horizant |
| Forte Bio-Pharma LLC | $54.75 | 2022 | |
| Biodelivery Sciences International, INC. | $52.10 | 2021 | |
| Saluda Medical Americas, INC. | $51.09 | 2025 | Evoke |
| Nevro Corp. | $46.28 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $42.90 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $29.79 | 2022-2023 | Quviviq |
| Bioventus LLC | $25.34 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $23.88 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.10 | 2022 | |
| Novo Nordisk INC | $20.81 | 2023 | Wegovy |
| Redhill Biopharma INC. | $17.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.32 | 2021 | |
| Lilly USA, LLC | $16.20 | 2022 | |
| Abbvie INC. | $14.47 | 2022 | |
| Pfizer INC. | $13.41 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.